Adalimumab: Amgevita the principal brand
From 1 October 2022, Amgevita became the main funded brand of adalimumab. Most people taking adalimumab have moved from the Humira brand to Amgevita.
Benefits of moving to Amgevita
More people can access Amgevita and existing patients can access higher doses of treatment.
Amgevita is a citrate-free version of adalimumab. This means some people using this medicine may find it less painful to use.
Moving from Humira to Amgevita frees up a significant amount of Pharmac's fixed budget, which will be used to fund other medicines.
This is the Pharmac model in action. Competing markets, forecasting and moving to a biosimilar medicine stretches New Zealand’s medicine budget further and means we can fund more medicines for more New Zealanders.